
## Stephen Brand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5750837/publications.pdf Version: 2024-02-01



STEDHEN ROAND

#	Article	IF	CITATIONS
1	Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy. Science, 2022, 376, 1074-1079.	12.6	25
2	Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines. Journal of Medicinal Chemistry, 2021, 64, 4150-4162.	6.4	14
3	Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 5905-5930.	6.4	25
4	Design of proteasome inhibitors with oral efficacy in vivo against <i>Plasmodium falciparum</i> and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	19
5	Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity. Bioorganic Chemistry, 2021, 115, 105244.	4.1	11
6	The proteasome as a target for protozoan parasites. Expert Opinion on Therapeutic Targets, 2019, 23, 903-914.	3.4	32
7	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9318-9323.	7.1	119
8	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2019, 62, 1180-1202.	6.4	33
9	Pharmacological Validation of <i>N</i> -Myristoyltransferase as a Drug Target in <i>Leishmania donovani</i> . ACS Infectious Diseases, 2019, 5, 111-122.	3.8	55
10	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant <i>N</i> -Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 8374-8389.	6.4	41
11	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in <i>Leishmania donovani</i> . ACS Infectious Diseases, 2017, 3, 718-727.	3.8	22
12	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against <i>Trypanosoma cruzi</i> . Journal of Medicinal Chemistry, 2017, 60, 7284-7299.	6.4	31
13	Design and Synthesis of Brain Penetrant Trypanocidal <i>N</i> -Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 9790-9806.	6.4	14
14	Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2016, 10, e0004540.	3.0	25
15	Development of Smallâ€Molecule <i>Trypanosoma brucei N</i> â€Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. ChemMedChem, 2015, 10, 1821-1836.	3.2	20
16	Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0004014.	3.0	43
17	Lead Optimization of a Pyrazole Sulfonamide Series of <i>Trypanosoma brucei</i> <i>N</i> -Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014. 57. 9855-9869.	6.4	57
18	Discovery of a Novel Class of Orally Active Trypanocidal <i>N</i> -Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 140-152.	6.4	102

#	Article	IF	CITATIONS
19	N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.	27.8	272